PlainRecalls
FDA Drug Low Class III Terminated

Clindamycin Injection, USP, 300 mg/ 2 mL (150 mg/mL), 2 mL vials, Rx only, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA.,NDC 47781-619-94

Reported: April 10, 2019 Initiated: March 15, 2019 #D-1070-2019

Product Description

Clindamycin Injection, USP, 300 mg/ 2 mL (150 mg/mL), 2 mL vials, Rx only, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA.,NDC 47781-619-94

Reason for Recall

Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

Details

Recalling Firm
Pfizer Inc.
Units Affected
701 cartons (25 vials per carton)
Distribution
Nationwide USA and Guam
Location
New York, NY

Frequently Asked Questions

What product was recalled?
Clindamycin Injection, USP, 300 mg/ 2 mL (150 mg/mL), 2 mL vials, Rx only, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA.,NDC 47781-619-94. Recalled by Pfizer Inc.. Units affected: 701 cartons (25 vials per carton).
Why was this product recalled?
Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point
Which agency issued this recall?
This recall was issued by the FDA Drug on April 10, 2019. Severity: Low. Recall number: D-1070-2019.